Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Antimicrobial company Zoono (ZNO) has appointed Linco Investments as its exclusive distributor for Singapore
  • Singapore is an important market for Zoono as it is a recognised hub of the Association of Southeast Asian Nations country group
  • When applied, Zoono’s technology bonds with any surface on which it is applied to, then attracts and kills bacteria
  • The five-year distribution agreement will be available in all markets in Singapore
  • Under the deal, minimum purchase orders will start at $1.4 million
  • Zoono’s share price has jumped 24 per cent today with shares trading for $2.40 apiece

Zoono (ZNO) has appointed Linco Investments as its exclusive distributor for Singapore.

Linco Investments is a Singaporean based facilities and management company with roots dating back to 1988.

Linco’s group of companies are involved in the importation, distribution and supply to government agencies, private companies and business to consumer markets (B2C).

Singapore is an important market for Zoono as it is a recognised hub of the ASEAN (Association of Southeast Asian Nations) country group and a lot of companies’ head offices are located there.

Following the outbreak of the coronavirus, now named COVID-19, there continues to be exceptional interest in Zoono’s technology and its efficacy against bacteria and viruses.

Results from the German laboratory, testing the technology against the current strain of coronavirus, are expected soon.

When applied, Zoono’s technology leaves behind a mono-molecular layer that bonds with any surface on which it is applied to then attracts and destroys bacteria and pathogens.

Its ‘physical kill’ replaces the need for dangerous chemicals, poisons and alcohols, and the method of rupturing the cell means it cannot mutate, preventing the development of superbugs.

The distribution agreement is for an initial five-year term and its exclusive in all markets in Singapore.

Minimum purchase volumes include NZD$1.5 million (AUD$1.4 million) in the first 12 months, NZD$2 million (AUD$1.9 million) in year two, and NZD$2.6 million (AUD$2.4 million) in year three.

After this, the purchase volumes in the years following will increase by 10 per cent per annum.

Full payment is required for all the products before they are shipped and NZD$400,000 (AUD$383,699) has already been paid for its initial orders.

Zoono’s share price has jumped 19.4 per cent with shares trading for $2.31 apiece at 11:57 am AEDT.

ZNO by the numbers
More From The Market Herald

" Zelira Therapeutics (ASX:ZLD) releases HOPE trial data

Zelira Therapeutics’ (ASX:ZLD) latest trial results have shown patients with ASD achieved moderate therapeutic effect while…

" Nyrada (ASX:NYR) edges closer to European patent for cholesterol management drug

Nyrada Inc (NYR) has received a Notice of Intention from the European Patent Office (EPO) to…
Hydrix (ASX:HYD) - Executive Chairman, Gavin Coote

" Hydrix (ASX:HYD) signs partnership with Scandinavian Realheart to develop Total Artificial Heart

Hydrix (ASX:HYD) has signed a long-term partnership agreement with Scandinavian Realheart, a Swedish company developing the…

" Incannex Healthcare (ASX:IHL) receives new FDA advice for sleep apnoea treatment

Incannex Healthcare (ASX:IHL) has been given fresh guidance from the US Food and Drug Administration (FDA)…